Lipocine (LPCN)
(Delayed Data from NSDQ)
$4.55 USD
+0.11 (2.48%)
Updated Apr 25, 2024 03:59 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for Lipocine Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -16.35 | -10.76 | -0.63 | -20.96 | -13.01 |
Depreciation/Amortization & Depletion | -0.92 | -0.11 | 0.52 | 0.00 | -0.15 |
Net Change from Assets/Liabilities | 2.01 | -0.92 | -4.59 | 1.52 | 0.47 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.40 | -0.17 | 0.30 | 4.14 | 1.02 |
Net Cash From Operating Activities | -11.87 | -11.97 | -4.41 | -15.30 | -11.67 |
Property & Equipment | -0.01 | -0.13 | -0.01 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 13.10 | 14.43 | -43.77 | 3.89 | 3.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 13.08 | 14.29 | -43.78 | 3.89 | 3.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.40 | 0.21 | 30.26 | 22.33 | 13.65 |
Issuance (Repayment) of Debt | 0.00 | -1.67 | -3.33 | -1.43 | -3.33 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -0.67 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.40 | -2.13 | 26.92 | 20.90 | 10.32 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 1.62 | 0.20 | -21.27 | 9.49 | 1.65 |
Cash at Beginning of Period | 3.15 | 2.95 | 24.22 | 14.73 | 13.08 |
Cash at End of Period | 4.77 | 3.15 | 2.95 | 24.22 | 14.73 |
Diluted Net EPS | -3.14 | -2.21 | -0.17 | -6.46 | -8.50 |
Fiscal Year End for Lipocine Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -16.35 | -14.07 | -7.42 | -3.87 |
Depreciation/Amortization & Depletion | NA | -0.92 | -0.73 | -0.50 | -0.25 |
Net Change from Assets/Liabilities | NA | 2.01 | 1.53 | 0.46 | 0.11 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 3.40 | 3.42 | 0.22 | 0.08 |
Net Cash From Operating Activities | NA | -11.87 | -9.84 | -7.24 | -3.93 |
Property & Equipment | NA | -0.01 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 13.10 | 10.36 | 9.12 | 5.56 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 13.08 | 10.36 | 9.12 | 5.55 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.40 | 0.41 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | -0.01 | -0.01 |
Net Cash from Financing Activities | NA | 0.40 | 0.41 | -0.01 | -0.01 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 1.62 | 0.92 | 1.87 | 1.62 |
Cash at Beginning of Period | NA | 3.15 | 3.15 | 3.15 | 3.15 |
Cash at End of Period | NA | 4.77 | 4.07 | 5.01 | 4.77 |
Diluted Net EPS | NA | -0.51 | -1.27 | -0.68 | -0.68 |